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Streptavidin is one of the most important hubs for molecular biology, either multimerizing biomolecules,
bridging one molecule to another, or anchoring to a biotinylated surface/nanoparticle. Streptavidin has the
advantage of rapid ultra-stable binding to biotin. However, the ability of streptavidin to bind four biotinylated
molecules in a heterogeneous manner is often limiting. Here, we present an efficient approach to isolate
streptavidin tetramers with two biotin-binding sites in a precise arrangement, cis or trans. We genetically
modified specific subunits with negatively charged tags, refolded a mixture of monomers, and used
ion-exchange chromatography to resolve tetramers according to the number and orientation of tags. We
solved the crystal structures of cis-divalent streptavidin to 1.4 Å resolution and trans-divalent streptavidin to
1.6 Å resolution, validating the isolation strategy and explaining the behavior of the Dead streptavidin variant.
cis- and trans-divalent streptavidins retained tetravalent streptavidin's high thermostability and low off-rate.
These defined divalent streptavidins enabled us to uncover how streptavidin binding depends on the nature of
the biotin ligand. Biotinylated DNA showed strong negative cooperativity of binding to cis-divalent but not
trans-divalent streptavidin. A small biotinylated protein bound readily to cis and trans binding sites. We also
solved the structure of trans-divalent streptavidin bound to biotin-4-fluorescein, showing how one ligand
obstructs binding to an adjacent biotin-binding site. Using a hexaglutamate tag proved a more powerful way to
isolate monovalent streptavidin, for ultra-stable labeling without undesired clustering. These forms of
streptavidin allow this key hub to be used with a new level of precision, for homogeneous molecular assembly.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Introduction
Streptavidin isa tetramericprotein fromStreptomyces
avidinii [1] that, along with the structurally similar protein
from chicken egg white, avidin, exhibits extraordinarily
high affinity for the vitamin biotin [2,3]. The femtomolar
affinity of streptavidin/avidin for biotinylated targets,
combined with resilience to harsh conditions and an
on-rate of ~107 M−1 s−1, is thebasis for biotin's central
role as a specific biological “glue” in diverse research
methods and biotechnologies [1–3].
Although streptavidin has a long history of use for
capture of biotinylated ligands from complexmixtures,
it has gainedmany recent applications for precise and
stable assembly in the emerging field of bionanotech-
nology [4–6]. Such assemblies can be centered on a
single streptavidin, for example, streptavidin:MHC
(major histocompatibility complex) tetramers, to ana-atter © 2013 The Authors. Published by Ellyze immune function [7]. Assemblies can also depend
on multiple streptavidin molecules holding together
networks, such as for amplification in histochemistry [8]
or to bridge biomolecules to facilitate structure deter-
mination by electron microscopy, atomic force micros-
copy, and X-ray crystallography [9–11].
A central issue that needs addressing is to control
the nature of the four binding sites in the streptavidin
tetramer. While the binding of four ligands may be
desirable in some applications, in other applications,
it may be necessary to limit binding to only one, two,
or three subunits to achieve the desired assemblies
and geometries [11–13]. Splitting up the streptavidin
tetramer into monomers or dimers is possible, but
this has always been accompanied by orders of
magnitude lower affinity for biotin [14–17], because
of the contribution of the neighboring subunit to the
biotin-binding site [1,18]. Such monomers or dimerssevier Ltd. All rights reserved. J. Mol. Biol. (2014) 426, 199–214
Fig. 1. Principle of defined divalent streptavidins.
Numbering of subunits in the streptavidin tetramer, with
each monomer colored separately and biotin in space-fill
(from PDB ID: 3RY2). Below are arrangements of 1,2 or
1,3 biotin-binding sites (biotin-bound monomers, green;
non-binding monomers, blue), showing relative orienta-
tions and distances between the biotin carboxyl group
carbons.
200 Crystal Structures of Divalent Streptavidinsgive desirable reversibility for purification but forfeit
much of the advantage of streptavidin's stability for
assembly applications.
We previously generated streptavidin heterotetra-
mers with exactly one, two, or three functional biotin-
binding sites, through purifying tetramers containing
defined numbers of non-biotin-binding “Dead” and
His6-tagged wild-type subunits [19]. However, tetra-
mers with two functional and two Dead subunits can
assemble in three different arrangements. These
arrangements are the 1,2, 1,3, and 1,4 divalent forms
of streptavidin (Fig. 1). In the 1,2 arrangement the
biotin-binding sites of streptavidin are in a cis config-
uration as the binding sites both point in the same
direction (Fig. 1). However, in the 1,3 arrangement,
both sites are in a trans configuration, pointing away
from each other (Fig. 1). Taking a vector fromN1 to the
terminal carbon atom of biotin, in 1,2, both biotins point
23° from the two-fold axis in Fig. 1, while in 1,3, one
biotin is 23° from this axis and the other is 160°. In 1,2,
the terminal carbon atoms of the two biotins are 20 Å
apart, and in 1,3, they are 35Åapart (Fig. 1). Therefore,
any biotinylated ligands to divalent streptavidin will
adopt different distances and angles with respect to
each other. Such mixed divalent species, containingall three arrangements, would not be suitable for
applications where defined spatial control is neces-
sary. For example, a cis arrangement may be suitable
for capping biotinylated protein oligomers [20], result-
ing in molecules with a uniform length, while the trans
arrangement may serve as a linker in the middle of
such an assembly [20,21].
Control over subunit orientation could be achieved
by generating single-chain dimers or tetramers [22],
but the symmetry and folding characteristics of
streptavidin mean that connection of subunits (using
circular permutation) has been accompanied by
impaired folding and affinity [16,23].
To generate a controlled and stable bridge for
bionanotechnology, we demonstrate here a method
for the simple isolation of streptavidin variants with
precise cis-divalent or 1,3 trans-divalent arrange-
ments. We confirmed the variant structures by
crystallography and investigated the binding char-
acteristics of these defined divalents, which helps to
resolve decades of data about interaction between
binding sites on streptavidin/avidin [24–28].Results
Streptavidins with defined valencies and subunit
orientation by engineering of charge
To prepare streptavidin tetramers with controlled
pairs of biotin-binding sites (Fig. 1), we added charged
tags at specific sites in the subunits to enable resolution
of the tetramers by ion-exchange chromatography
(Figs. 2 and 3). We refolded from inclusion bodies the
mixture of charged and non-charged streptavidin
variants and then separated the tetramers on a
MonoQ column (anion exchange), since the tetramers
with increasing negative charge required higher ionic
strength for elution. Geometrically distinct species
bearing the same number of charged tags can be
separated from each other. On that basis, two different
engineering strategies made it possible to isolate the
cis-divalent and 1,3 trans-divalent forms (Fig. 1).
C-terminal polyglutamate tag allowed 1,3
trans-divalent isolation
In the first instance, we placed a hexaglutamate
tag at the C-terminus of core streptavidin monomer
(termed SAe) (Fig. 2a). First, these charges ought to
allow easy isolation of forms containing 0–4
biotin-binding sites by ion-exchange chromatogra-
phy, giving clearer separation than the previous
method of separation using a C-terminal His6 tag
and Ni-NTA, where peaks from different tetramer
forms largely overlapped [19,29]. Second the
C-termini are close together between subunits 1
and 3 (27 Å) but far apart between subunits 1 and 2
Fig. 2. Generation of the 1,3 trans-divalent streptavidin. (a) Amino acid sequence of streptavidin-E6 (SAe) with E6 tag red and
underlined, along with Dead (D) streptavidin showing residues impairing biotin binding in blue. (b) Generation of the different
valency formsofSAe/Dbymixed refoldand ionexchange,with predictedpIofmonomerand tetramer indicated. (c) Ion-exchange
chromatogramof amixtureof tetramers containingdifferent proportions of SAeandD. (d)Analysis of peaks from ionexchangeby
SDS-PAGE with Coomassie staining, unboiled (left) to show tetramer mobility, or boiled (right) to show subunit composition.
201Crystal Structures of Divalent Streptavidins(57 Å) or subunits 1 and 4 (50 Å), so that elution from
the ion-exchange resin would be predicted to occur
later for the 1,3 divalent (Fig. 1).
SAe was refolded together with Dead (D) strepta-
vidin (N23A, S27D, S45A) [19] (Fig. 2a). Seven
different tetramer forms are possible: one nullivalent,
one monovalent, one trivalent, one tetravalent, and
three divalent (Fig. 2b). The ion-exchange chro-
matogram showed six peaks (Fig. 2c), consistent
with our hypothesis that 1,2 and 1,4 divalents would
co-elute, while the 1,3 divalent would elute later.
We analyzed the eluted peaks by SDS-PAGE,
where streptavidin will remain a tetramer withoutboiling (Fig. 2d) [30]. The tetramers do not run
according to their molecular weight: the increasing
negative charge increases migration of tetramers
containing a higher proportion of SAe. Upon boiling in
SDS, the tetramer breaks up into monomers and the
relative proportion of SAe and D subunits is shown
(Fig. 2d). This gel analysis confirmed that peak 1 was
D4, peak 2 was the monovalent SAe1D3, peak 5 was
the trivalent SAe3D1, peak 6 was the tetravalent
SAe4, and peaks 3 and 4 were both divalent. A
titration with biotin-4-fluorescein (whose fluorescence
is quenched dramatically upon streptavidin binding)
[31,32] confirmed the expected number of biotin-
Fig. 3. Generation of cis-divalent streptavidin. (a) Amino acid sequence of core streptavidin (SA), along with Dead
(Dd) containing a polyaspartate insertion in the 3/4 loop (red and underlined) and residues impairing biotin binding in
blue. (b) Generation of the different valency forms of SA/Dd by mixed refold and ion exchange, with predicted pI of
monomer and tetramer indicated. (c) Ion-exchange chromatogram of a mixture of tetramers containing different
proportions of SA and Dd. (d) Analysis of peaks from ion exchange by SDS-PAGE with Coomassie staining, unboiled
(left) to show tetramer mobility, or boiled (right) to show subunit composition.
202 Crystal Structures of Divalent Streptavidinsbinding sites for D4, SAe4, SAe1D3, and the putative
1,3 trans-divalent (Supplementary Data Fig. S1a).
Multiple aspartates in a surface loop allowed
cis-divalent isolation
To isolate cis-divalent streptavidin (1,2 arrangement
of biotin-binding subunits) (Fig. 1), we introduced a
series of aspartates into the loop between β-strands 3
and 4 (L3,4) of the Dead subunit (Fig. 3a). After
exploring a number of different insertions for optimal
expression and separation, we chose the sequencetermed Dd (Fig. 3a). Introduction of the charges in this
position means that in the 1,3 and 1,4 arrangements,
these charged regions should be far apart, while in the
1,2 arrangement, the charged loops should be
apposed (Fig. 3b). Since L3,4 is important for biotin
binding affinity [1,18,33], it was necessary to insert
these residues on the Dead subunit, so that the
cis-divalent streptavidin could maintain high biotin
binding affinity. Ion-exchange chromatography of a
mixed refold of SA/Dd again allowed efficient separa-
tion of tetramers, giving six peaks, two of which
corresponded to divalent species (Fig. 3b and c).
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without boiling. For unboiled samples, the negative
charge on Dd accelerated the mobility of the
tetramers (Fig. 3d). Upon boiling, the varying
intensities of SA and Dd bands clearly showed that
the tetramers contained the expected ratios of each
subunit (Fig. 3d). This gel analysis confirmed that
peak 1 was tetravalent SA4, peak 2 was the trivalent
SA3Dd1, peak 5 was the monovalent SA1Dd3, peak
6 was the non-binding Dd4, and peaks 3 and 4 were
both divalent. A titration of the different tetramer
forms with biotin-4-fluorescein also confirmed the
expected number of biotin-binding sites (Supple-
mentary Data Fig. S1b). Overall, the introduction of a
series of negative charges into the surface-exposed
3,4-loop of streptavidin allowed the isolation of a
second divalent species, cis-divalent.Fig. 4. Crystal structures of divalent streptavidins. (a) Elect
27, and 45 in the 1,3 trans-divalent structure shown for chains b
found indicated below. (b) Crystal structure of the 1,3 trans-diva
subunits and blue showing the non-biotin-binding D subunits. (
b/d (SA, green) and chains a/c (Dd, blue). (d) Crystal struc
biotin-binding SA subunits and blue showing the non-biotin-biCrystal structures of cis-divalent and 1,3
trans-divalent streptavidins
To confirm these divalent arrangements suggested
by the ion-exchange elution profiles, we solved at high
resolution the crystal structures of the 1,3 trans- and
cis-divalent streptavidin (Fig. 4). Initially, all our crystal
forms only contained two subunits in the asymmetric
unit, which did not allow us to distinguish the possible
divalent forms. However, one condition obtained using
the Morpheus crystal screen [34] yielded the desired
asymmetric unit for the cis-divalent streptavidin
containing all four subunits. For the 1,3 trans-divalent
form, crystallization with 2-methyl-2,4-pentanediol
(MPD) gave us the desired asymmetric unit [35]. The
obtained 1,3 trans-divalent crystal structure was
solved at 1.6 Å resolution (Fig. 4b and Table 1), andron density (2Fo − Fc contoured at 1 rmsd) at residues 23,
/c (SAe, green) and chains a/d (D, blue), with the side chain
lent streptavidin, with green showing the biotin-binding SAe
c) Electron density in the cis-divalent structure, with chains
ture of cis-divalent streptavidin, with green showing the
nding Dd subunits.
Table 1. Data collection, refinement statistics, and structure validation for the 1,3 trans-divalent and cis-divalent
streptavidin structures.
1,3 trans-divalent
(4BX6)
cis-divalent
(4BX5)
1,3 trans-divalent with
biotin-4-fluorescein (4BX7)
Data collection
Space group P1211 P1211 P3121
Asymmetric unit Tetramer Tetramer Dimer
Unit cell size (Å) 47.04 × 81.59 × 65.12 46.22 × 84.24 × 58.25 64.41 × 64.41 × 103.13
Unit cell angles (°) 90 × 95.94 × 90 90 × 98.81 × 90 90 × 90 × 120
Completeness (%) 98.00 92.59 99.77
Refinement
Resolution (Å) 1.59–24.98 1.43–42.12 2.26–49.06
No. of reflections 64,074 75,108 12,059
Rwork/Rfree 0.1640/0.1866 0.1601/0.1873 0.1839/0.2369
No. of atoms
Protein 3756 3739 1768
Heteroatoms 24 42 54
Water 466 517 78
B-factors (mean of all atoms, Å2)
Wilson plot 20.98 14.65 42.43
Mean B value 28.40 22.00 45.10
rmsd
Bond length (Å) 0.011 0.01 0.01
Bond angle (°) 1.28 1.14 0.94
Structure validation
MolProbity clash score 3.65 (97th percentile) 2.71 (98th percentile) 2.29 (100th percentile)
Poor rotamers (%) 2.01 0.57 2.33
Ramachandran outliers (%) 0.43 0.00 0.00
Ramachandran favored (%) 97.02 97.65 97.85
MolProbity score 1.55 (85th percentile) 1.13 (98th percentile) 1.32 (100th percentile)
Residues with bad bonds (%) 0.00 0.00 0.00
Residues with bad angles (%) 0.00 0.00 0.00
204 Crystal Structures of Divalent Streptavidinscis-divalent streptavidin was solved at 1.4 Å resolution
(Fig. 4d and Table 1), with the phases in each case
solved using molecular replacement.
We identified each subunit (whether SAe/D or SA/
Dd) unambiguously by examiningwhether the electron
density around residues 23, 27, and 45 corresponded
to the residues of the wild-type or Dead subunit (N23A,
S27D, S45A). For the putative 1,3 trans-divalent, the
electron density closely fitted residues 23, 27, and 45
only if chains b/c were SAe and chains a/d were D
(Fig. 4a), confirming that the biotin-binding subunits
indeed had a 1,3 trans orientation (Fig. 4b). For the
putative cis-divalent sample, the electron density
closely fits if chains a/c are Dd and chains b/d are SA
(Fig. 4c), also confirming that the biotin-binding
subunits indeed had a cis orientation (Fig. 4d).
Furthermore, while the electron density around
L3,4 could be clearly observed in the SA chains b
and d of the cis-divalent form, the electron density of
L3/4 was poorly defined in Dd chains a and c
(Supplementary Data Fig. S2). The engineered L3,4
of Dd (chains a/c) is expected to be highly flexible,
which would lead to weak diffraction in this region.
The rmsd of any of the chains in 1,3 trans-divalent
and cis-divalent streptavidin is less than 0.5 Å to chain
a of the 0.95-Å structure of streptavidin [Protein Data
Bank (PDB) ID: 3RY2] [35]. The Dead streptavidin
subunit has not been previously analyzed by crystal-lography, and the changes to the structure are
localized to the mutated residues, consistent with
the comparable thermostability of tetramers contain-
ing wild-type or Dead subunits [19,33]. The overlay of
D and a wild-type subunit bound to biotin illustrates
how the three mutations in D greatly reduced the
number of polar contacts to biotin (Fig. 5a). In the
overlay, Asp27 has van der Waals clash with biotin
and there would be repulsion between the Asp27
carboxylate and biotin's carbonyl oxygen lone pair
(Fig. 5a).
Crystal structure of biotin-4-fluorescein bound
to streptavidin
To understand interaction between ligand binding
sites, we solved 1,3 trans-divalent streptavidin's
crystal structure bound to biotin-4-fluorescein. Bio-
tin-4-fluorescein represents the largest ligand where
there is a crystal structure with streptavidin or avidin,
as well as a widely used probe of the binding kinetics
and capacity of biotin-binding proteins [19,31,32,36–
38]. The fluorescence of biotin-4-fluorescein is
quenched ~90% on binding to streptavidin/avidin,
allowing a clear and sensitive test of ligand
binding without any separation step [31,32]. Our
2.3-Å-resolution structure shows the 1,4 dimer in the
asymmetric unit (one copy of SAe and one copy of
Fig. 5. Structures of streptavidin interaction with ligands. (a) Structure of the biotin-binding pocket in the Dead subunit
(N23A, S27D, and S45A), showing chain a of the 1,3 trans-divalent streptavidin (carbon atoms in blue) overlaid with
biotin-bound wild-type streptavidin (PDB ID: 3RY2, carbon atoms in yellow). Hydrogen bonds from residues 23, 27, and 45
to biotin in wild-type streptavidin are shown as broken lines. (b) Crystal structure of the 1,3 trans-divalent streptavidin
bound to biotin-4-fluorescein (space-fill, carbons in cyan), with green for SAe and blue for D subunits. (c) Residues
surrounding the fluorescein tail (carbon atoms in cyan) in the 1,3 trans-divalent:biotin-4-fluorescein structure, labeled
according to chain (b, carbon atoms in green; d, carbon atoms in blue), and with putative interactions as broken lines.
Electron density for biotin-4-fluorescein is shown as blue mesh and contoured at 1 rmsd. (d) Clash for cis-bound
biotin-4-fluorescein, generated from the 1,3 trans-divalent biotin-4-fluorescein structure, if two biotin-4-fluorescein
molecules (carbon atoms of one in yellow and the other in cyan) were to bind in the same conformation in cis as they do in
1,3 trans-divalent.
205Crystal Structures of Divalent StreptavidinsD). Building the native streptavidin tetramer from this
dimer shows that the two biotin-4-fluorescein mole-
cules are in the expected trans (1,3) arrangement
(Fig. 5b). All the contacts of the 1,3 trans-divalent
streptavidin with the biotinmoiety are as expected [18].
Fluorescein and the ethylene diamine spacer form
several non-polar contacts to streptavidin not observed
with biotin (Fig. 5c). Features that have been proposed
to quench fluorescein are photoinduced electron
transfer to nearby tryptophans or tyrosines [39],
co-planarity of the xanthenone and benzoate rings
[40], and hydrogen bonding to O3 of fluorescein [41].
Trp120 is 5 Å from fluorescein (Fig. 5c) and may
explain part of the quenching of fluorescence.
Biotin-4-fluorescein bound in chain b reaches over
and interactswith residues of chain d. However, wedo
not believe this conformation of biotin-4-fluorescein is
the same as when four ligands are bound to the sametetramer: if the SAe:biotin-4-fluorescein complex were
in a cis arrangement, there would be an obvious clash
between the fluorescein moieties of neighboring
ligands (Fig. 5d).
Low off-rate and high thermostability of
defined divalents
Having confirmed the identity of the defined diva-
lents, we initially assessed these proteins by measur-
ing the off-rate for a biotin conjugate (Fig. 6a). The
strong biotin-binding stability of wild-type streptavidin
was retained by the defined divalents. Both divalents
had dissociation rates for biotin-4-fluorescein compa-
rable to the original SA4 or SAe4 tetramers. In fact, the
binding stability for the 1,3 trans-divalent streptavidin
was slightly superior to that of the cis-divalent one
(P ≤ 0.001, n = 3) and that of the wild-type SA4
Fig. 6. Off-rate and thermostability of divalent streptavidins. (a) Biotin-4-fluorescein dissociation over time at 37 °C in
the presence of competing biotin, for a tetramer of wild-type streptavidin subunits (SA4), a tetramer of SAe subunits
(SAe4), and cis-divalent or 1,3 trans-divalent streptavidin (mean of triplicate + 1 SD). (b) Tetramer thermostability for
streptavidin variants determined by SDS-PAGE with Coomassie staining, following incubation in PBS for 3 min at the
indicated temperatures. In B, the protein was boiled in the presence of SDS to achieve complete conversion to monomers.
The mobilities of the starting tetramer and the resulting monomers are marked.
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Tukey's multiple comparison) (Fig. 6a).
We next compared the thermostability of the two
divalent forms with tetramers containing only the
constituent monomers. We incubated at varying
temperatures and then analyzed the resulting protein
forms by SDS-PAGE (Fig. 6b). Both cis-divalent and
1,3 trans-divalent forms started to denature to theirconstituent monomers above 70 °C, in a similar
fashion to SA4, Dd4, SAe4, and D4. Some mixing of
the divalent tetramers into new species could be
observed at 70 °C before full denaturation into the
monomer species (Fig. 6b). To check whether this
mixing would be an issue at 37 °C or room temper-
ature, we incubated cis-divalent and 1,3 trans-divalent
streptavidins for 1–8 days, but we observed no
Fig. 7. Differential binding of biotinylated molecules by divalent streptavidins. (a) A monobiotinylated PCR product
(50 nM) was incubated with 1,3 trans- or cis-divalent streptavidin (100 nM) for the indicated times at 37 °C and then
analyzed by agarose gel electrophoresis, with ethidium bromide visualization of DNA. C is a control of DNA without
streptavidin. (b) Titration of the biotinylated PCR product (50 nM) with varying amounts of 1,3 trans-divalent (upper panel)
or cis-divalent (lower panel) streptavidin for 16 h at 25 °C, analyzed by electrophoresis as in (a). (c) Native PAGE of
monobiotinylated affibody titrated with 1,3 trans-divalent (upper panel) or cis-divalent (lower panel) streptavidin, analyzed
by Coomassie staining. (d) Comparison of the relative sizes of an affibody (PDB ID: 2KZJ, space-fill), a short segment of
B-form DNA (PDB ID: 1BNA, space-fill), and the separation between cis-binding sites on streptavidin (PDB ID: 3RY2,
protein in gray, biotin in red, Connolly surface).
207Crystal Structures of Divalent Streptavidinsdetectable dissociation to rearranged tetramers or to
constituent monomers (Supplementary Data Fig. S3).
Binding of large biotinylated ligands by defined
divalent streptavidins
To characterize further the interaction between the
two biotin-binding sites of cis-divalent and 1,3
trans-divalent streptavidin, we examined the capture
of larger biotinylated ligands. Binding of a mono-biotinylated 439-bp PCR product was analyzed by a
mobility shift in agarose gel electrophoresis (Fig. 7a).
The 1,3 trans-divalent streptavidin bound two DNA
molecules almost immediately. The cis-divalent form
bound one DNA molecule rapidly, but binding of a
second DNA molecule was very slow (Fig. 7a). A
similar pattern was observed when titrating the
biotinylated DNA with varying concentrations of each
divalent streptavidin. While the 1,3 trans-divalent
streptavidin preferentially bound two molecules of
208 Crystal Structures of Divalent StreptavidinsDNA, the cis-divalent formboundoneor twomolecules
(Fig. 7b).
We also analyzed binding of a biotinylated protein,
avoiding the high charge of polynucleotides. Titration of
thedivalentswith asite-specifically biotinylatedaffibody
[42], analyzed by the mobility shift in native PAGE,
yielded a similar pattern (Fig. 7c). With streptavidin
binding sites in excess, one or two molecules of the
monobiotinylated affibody could bind to the 1,3
trans-divalent streptavidin, while for the cis-divalent
one, only a single affibody bound. However, at higher
concentrations of affibody, two molecules of affibody
bound to the cis-divalent form (Fig. 7c). The sizes of the
affibody and DNA double helix relative to streptavidin
are illustrated in Fig. 7d.
Monovalent streptavidin isolatedby ion-exchange
chromatography allowed specific cellular imaging
Monovalent streptavidin has found diverse uses,
such as a highlighter in electron microscopy [43],
calibrating energies in protein folding [44], enhancing
antibody detection sensitivity [45], and DNA origami-
mediated nano-assembly [46]. The clean resolution of
monovalent streptavidin SAe1D3 from other valency
forms by ion-exchange chromatography (Fig. 2c) is
superior to our previous Ni-NTA method, where
elution of His6-tagged monovalent and divalent
forms substantially overlapped [19,29]. Therefore,
we validated that the new SAe1D3 form was still
effective for cellular imaging and the altered charge
did not lead to high non-specific cellular binding. HeLa
cells were transfected with ER-resident biotin ligase
and acceptor peptide-tagged low-density lipoprotein
receptor (LDLR) [29] and then imagedwith AlexaFluor
555-labeled SAe1D3. SAe1D3 clearly labeled cells
expressing AP-GFP-LDLR but did not label nearby
non-expressing cells or cells that were not co-trans-
fected with biotin ligase (Supplementary Data Fig.
S4), consistent with specific biotin detection.Discussion
Herein, we describe the generation and analysis of
tetramers of streptavidin with a defined orientation of
twin biotin-binding sites. We were able to engineer
cis-divalent streptavidin with comparably low biotin
off-rate to wild-type streptavidin but 1,3 trans-
divalent streptavidin showed even better binding
stability. Defined divalent streptavidins should act as
an efficient and simple bridge for diverse applica-
tions in bionanotechnology.
Although new in its application to streptavidin, the
separation of multimers by ion-exchange chromatog-
raphy according to the position of charged tags
has been applied previously [47–49]. A similar
orientation-dependent separation was observed for
wild-type streptavidin tetramers containing two boundbiotins because of biotin's charge. However, the biotin
occupancy of such streptavidin tetramers changed
over hours [27], whereas our defined divalents were
stable for at least a week at 37 °C and should be
stable indefinitely at −80 °C. We found high thermo-
stability of both divalent tetramers, with negligible
dissociation into monomers until above 60 °C.
The introduced mutations have also not reduced
biotin-conjugate binding affinity, a problem frequently
encountered when engineering streptavidin [14–17].
Despite testing several strategies to isolate 1,4
divalent streptavidins, we could never attain a clean
separation. However, we anticipate that the most
important thing is having one defined trans-divalent
streptavidin, since the biotin–biotin separation distance
for 1,3 and 1,4 is very close.
The work here also establishes a substantially
improved route to monovalent streptavidin. Monova-
lent streptavidin with an E6 tag can be purified on a
larger scale compared to the His6-tagged monovalent
streptavidin, because its elution is well separated from
divalent streptavidin. SAe1D3 is alsoeasier to analyze
for purity, because it is much better resolved on
SDS-PAGE. The E6 tag did not impair the use of
monovalent streptavidin for specific cellular imaging.
Divalent streptavidins without defined orientation
have been used for generating monovalent quantum
dots [50] and for studying mechanical interactions
between MHC class I and T-cell receptors [51],
illustrating areas where our defined divalents would
improve control in nano-assembly.
Streptavidin and avidin are the most widely used
biotin-binding proteins, but recently, several others
have been found, including the dimers rhizavidin [52]
and shwanavidin [53]. These relativesmay find a range
of applications, but the natural dimers contain disulfides
and provide only one divalent orientation (equivalent to
1,4), and streptavidin appears to have stronger binding
to biotin conjugates [53,54]. A further advantage of
retaining the whole streptavidin tetramer is the possi-
bility in futurework to functionalizeDead subunits, such
as by fusion to an antibody fragment [55] or via an
exposed cysteine [56], to create a multifunctional hub.
The cooperativity that can exist for biotinylated ligand
binding is not well appreciated by the wider community
using streptavidin/avidin. For biotin itself, even though
streptavidin has a conformational change and in-
creased tetramer stability when biotin binds [18],
there is no cooperativity of biotin binding [27]. However,
for large biotinylated ligands, there can be substantial
negative cooperativity in binding to streptavidin/avidin,
as shown for biotin metal–ligand complexes [24].
Similarly, the binding of more than two biotinylated
DNA molecules to wild-type streptavidin was not
readily observed [5,57]. Our defined divalents allowed
direct analysis of these ligand–ligand repulsions at cis
or 1,3 trans binding sites. Binding of two large
biotinylated ligands was efficient for the 1,3 trans-
divalent streptavidin. Even with a ligand as small as
209Crystal Structures of Divalent Streptavidinsbiotin-4-fluorescein, our structure showed the interac-
tions that would inhibit cis binding. For moderate-sized
ligands, such as a biotinylated affibody, we found a
degree of negative cooperativity for cis binding. For a
larger and densely charged ligand such as biotinylated
DNA, binding in cis was both slow and required
substantial ligand excess. The two binding sites in
the cis-divalent streptavidin are 20 Å apart, and the
DNAdouble helix is 20 Å in diameter; hence, binding of
the first DNA molecule provides substantial steric and
electrostatic hindrance to binding of a second mole-
cule. In particular, the 1,3 trans-divalent form should be
preferable in generating precise DNA–streptavidin
assemblies, as only fully loaded complexes (two
DNA molecules per tetramer) were observed, rather
than heterogeneous mixtures seen with wild-type
streptavidin [5,57].
Numerous chemical (e.g., click chemistry) [58] and
biological (e.g., SNAP-tag [59], HaloTag [60,61],
SpyTag [62], and coiled coils [63]) approaches have
been developed in recent years for stable protein
assembly. However, streptavidin is still ubiquitous
because of the wide-ranging biotinylated resources
available and streptavidin's simple, nearly diffusion-
limited, and high-yield binding, enabling “plug and
play” construction. Our defined divalent streptavidins
should be valuable modules for researchers to
contrive novel nano-assemblies using nucleic
acids, proteins, sugars, and non-biological building
blocks [64].2www.addgene.orgMaterials and methods
Constructs
pET21-Core streptavidin (SA) [65] and pET21-Dead
streptavidin (D) [19] were used as templates for PCR with
KODHot Start polymerase (EMDMillipore). For theaddition
of a C-terminal hexaglutamate tag to core streptavidin to give
SAe (GenBank accession number KF378616), 5′-ATACA-
TATGGCTGAAGCTGGTATCACCGGCACCTGG and
5′-CGCAAGCTTTTATTACTCTTCCTCTTCCTCTTCG-
GAAGCAGCGGACGGTTTAACTTTGG were used. The
resulting PCR product was digested with NdeI and HindIII
and subcloned into pET21. We inserted a polyaspartate
loop into the Dead variant to give Dd (GenBank accession
number KF378617) using the Site-directed Ligase-Inde-
pendent Mutagenesis (SLIM) protocol [66] with 5′-GAT-
GACGATGGTGACGATGACGGTGATGACGATG-
G A G C T G A A T C T A G A T A C G T T C T G A C C ,
5′-GCTGAATCTAGATACGTTCTGACC, 5′-TCCATCGT-
CATCACCGTCATCGTCACCATCGTCATCACCAA-
CAGCGGCTTCGTAGGT , and 5 ′ - ACCAACA
GCGGCTTCGTAGGT. pET21b-AP-Affibody was made
by inverse PCR [67] from pET21b-ZSPA [68] with an
N-terminal acceptor peptide (AP tag, GLNDIFEAQ-
KIEWHE) for BirA-mediated biotinylation [69]. To intro-
duce mutations to bind IGF1R (type 1 insulin-like growth
factor receptor) [42], we generated AP-AffibodyIGF1R (Gen-
Bank accession number KF378618) using the forward primer5′-AATCGAAAACAGTCTACCGCATTTATTTCTAGCCTT-
GAAGATGACCCAAGCCAAAGCGCT and the reverse
primer 5′-TAGATTCGGTAATGCCAGGATTTCGATTG-
CAGCATAGAAACCTTCTTTGTTGAATTTGTTGTC.
Biotin ligase with a signal sequence and ER retention
sequence (pDisplay-BirA-ER) and pEGFP-AP-GFP-LDLR
(human LDLR containing an N-terminal acceptor peptide
and GFP) were previously described [70].
All constructs were verified by sequencing. Plasmids for
streptavidin constructs are available from Addgene:2 D
Plasmid 20859, SAe 46367, and Dd 46368.Protein expression and purification
SA, SAe, D, and Dd streptavidin variants were expressed
in Escherichia coli and refolded from inclusion bodies by
dilution into phosphate-buffered saline (PBS) as previously
described [29]. After refolding, the protein mixtures of SA/Dd
or SAe/Dwere first purified on a 5-mL iminobiotin-Sepharose
affinity column (Affiland, S.A.) using 50 mM sodium borate
and300 mMNaCl, pH 11.0, as thebindingbuffer and20 mM
KH2PO4, pH 2.2, as the elution buffer, with a 5-mL/min flow
rate. The eluate was then exchanged into 20 mM Tris–HCl,
pH 8.0, by dialysis and loaded onto a 1-mL Mono-Q column
(GE Healthcare). The different tetramers were then isolated
using a 100-column-volume (i.e., 100 mL) linear gradient of
0–1 M NaCl, collecting 1-mL fractions with a 1-mL/min flow
rate. For larger-scale preparations, a 30-mL Q-Sepharose
High-Performance column (GE Healthcare) and a
30-column-volume gradient from 0.15 to 0.4 M NaCl was
run. Eluted fractionswere concentrated to 5–10 mg/mL using
a Vivaspin cutoff 30-kDa centrifugal concentrator (GE
Healthcare), dialyzed thrice into PBS, and stored at −80 °C.
All purification steps were performed using an ÄKTA purifier
10 (GE Healthcare). Yield from refolding 1 L of biotin-binding
subunit mixed with 1 L of non-binding subunit was approx-
imately 9 mg of the relevant divalent and 12 mg of the
monovalent streptavidin.
Monovalent streptavidin (SAe1D3) can also be purified, if
preferred, in a gravity-flow column. The mixed refold of SAe
and D, prepared in 20 mM Tris–HCl, pH 8.0, as above, is
loadedonto 1 mLQ-SepharoseHigh-Performance resin (GE
Healthcare) in a Poly-Prep chromatography column
(Bio-Rad) pre-equilibrated with binding buffer of 20 mM
Tris–HCl, pH 8.0. The column is washed with 10 mL 20 mM
Tris–HCl, pH 8.0, plus 0.15 M NaCl (to wash out D4 and
impurities), followed by elution of SAe1D3 with 5 mL 20 mM
Tris–HCl, pH 8.0, plus 0.25 M NaCl, collecting 1-mL
fractions. The resin is regenerated by washing with 10 mL
20 mM Tris–HCl, pH 8.0, plus 2 M NaCl.
Glutathione S-transferase-BirA (the plasmid was a kind
gift from Chris O'Callaghan, University of Oxford) was
expressed in E. coli and purified using glutathione-
Sepharose as described previously [71]. AP-Affibody
was expressed in E. coli and purified using Ni-NTA
(Qiagen) [68]. Enzyme-mediated biotinylation was per-
formed as described previously [19].
Protein concentrations were determined from A280 via
ProtParam. Concentrations of all streptavidin forms refer to
the concentration of the monomer. pI was predicted using
ProtParam.
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SDS-PAGE was performed on 10% or 14% polyacryl-
amide gels, using an XCell SureLock system (Life Technol-
ogies). Protein samples (10 μM) for denaturation weremixed
with an equal volumeof 2×SDS loading buffer (20%glycerol,
100 mM Tris–HCl, 4% SDS, and 0.2% bromophenol blue,
pH 6.8) and heated for 3 min at 95 °C. Non-denatured
samples were loaded without boiling, in SDS-free loading
buffer. Gels were typically run for 1 h at room temperature at
200 V in running buffer (25 mM Tris–HCl, 192 mM glycine,
and 0.1% SDS, pH 8.2).
Biotinylated affibody and streptavidin were incubated at
the indicated concentrations in PBS for 16 h at 25 °C,
before mixing with an equal volume of 2× loading buffer
(20% glycerol, 100 mM Tris–HCl, and 0.2% bromophenol
blue, pH 6.8). Native PAGE was performed on 10%
polyacrylamide gels using standard running and loading
buffers but without SDS. Gels were stained with Instant-
Blue (Expedeon) and imaged using a ChemiDoc XRS
imager and QuantityOne (version 4.6) software
(Bio-Rad).Thermostability testing
Samples at 5 μM in PBS were heated at the indicated
temperature for 3 min in a DNA Engine® Peltier Thermal
Cycler (Bio-Rad). After cooling to room temperature,
samples were mixed with an equal volume of 2× loading
buffer (20% glycerol, 100 mM Tris–HCl, and 0.2%
bromophenol blue, pH 6.8). SDS-PAGE to discriminate
monomers from tetramers was performed on 14% poly-
acrylamide gels as previously described [36]. Wild-type
streptavidin samples heated for 3 min at 95 °C in the
presence of SDS were included as controls.
Divalent streptavidin crystallization and data collection
Apo 1,3 trans-divalent streptavidin crystals (space group
P1211; a = 47.04 Å, b = 81.59 Å, c = 65.12 Å, with two
SAe and two D monomers in the asymmetric unit) were
obtained from a 1-μL drop of a solution containing 0.5 μL of
740 μM 1,3 trans-divalent streptavidin in PBS mixed with
0.5 μL of reservoir solution, 65% v/v MPD, and 0.1 M
2-(N-morpholino)ethanesulfonic acid (Mes), pH 6.0. Crys-
tals were obtained by the sitting-drop vapor-diffusion
method at 291 K, reached a maximum size after
~10 days, and were harvested soon after.
For crystallization of 1,3 trans-divalent streptavidin with
biotin-4-fluorescein, we added biotin-4-fluorescein to a
final concentration of 100 μM along with 75 μM 1,3
trans-divalent streptavidin in PBS (0.5 mL final volume).
This sample was then concentrated 10-fold using a
Vivaspin cutoff 30-kDa centrifugal concentrator. Crystals
(space group P3121; a =64.41 Å, b = 64.41 Å, c =
103.13 Å, with one SAe and one D monomer in the
asymmetric unit) were obtained from a 1-μL drop of a
solution containing 0.5 μL 750 μM 1,3 trans-divalent
streptavidin mixed with 0.5 μL reservoir solution: 65% v/
v MPD and 0.1 MMes, pH 4.0. Crystals were obtained by
the sitting-drop vapor-diffusion method at 277 K, reached
a maximum size after ~14 days, and were harvested
soon after.Apo cis-divalent streptavidin crystals (space group
P1211; a = 46.22 Å, b = 84.24 Å, c = 58.25 Å, with two
SA and two Dd monomers in the asymmetric unit) were
obtained from a 0.1-μL drop of a solution containing
113 μM cis-divalent streptavidin and 28 μM ALAD-
Streptag [11] and a reservoir solution of 2.5% w/v
polyethylene glycol 1000, 12.5% w/v polyethylene glycol
3350, 12.5% v/v MPD, 30 mM of ethylene glycol mix
(di-ethyleneglycol, tri-ethyleneglycol, tetra-ethyleneglycol,
penta-ethyleneglycol), and 0.1 M Mes/imidazole, pH 6.5,
corresponding to condition E4 of the Morpheus screen [34].
Crystals appeared after 2 days and were harvested soon
after.
Prior to data collection, crystals were mounted and
immersed into liquid nitrogen. Crystallographic data were
collected at 100 K, using an Oxford Cryosystems 700
series Cryostream on an ADSC Quantum 315 charge-
coupled device detector with an oscillation range of 0.5° at
beamline iO4 at the Diamond Light Source, Didcot, UK.Structure solution and refinement
Data were auto-indexed and integrated by the xia2
program upon collection [72]. The cis- and 1,3 trans-
divalent streptavidin structures were phased by molecular
replacement using PDB 3RY1 (apo streptavidin) [35] and
further refined using the Phenix [73] suite of programs
implemented through a Python graphical user interface
[74]. The models were altered to better fit the electron
density using Coot [75]. Throughout the refinement of apo
1,3 trans-divalent, all data were included from 24.98 Å
resolution to the highest limit (1.59 Å), and anisotropic
temperature factors were refined. For the 1,3 trans-
divalent streptavidin with bound biotin-4-fluorescein, all
data from 49.06 Å resolution to the highest limit (2.26 Å)
and isotropic temperature factors were refined. Similarly,
for the cis-divalent structure, all data were included from
42.12 Å resolution to the highest limit (1.43 Å), and
anisotropic temperature factors were refined. All models
were continually evaluated with MolProbity [76].
The refinement statistics and other structure factors for
the two structures are shown in Table 1.
Structures were visualized, and images for figures were
prepared using PyMOL (Schrödinger, LLC). Electron
density maps were visualized and images were prepared
(contoured at 1 rmsd) with the CCP4mg program [77].
Predicting the clash between cis-bound biotin-4-fluorescein
molecules was done by overlaying the biotin-4-fluorescein-
bound streptavidin monomer with the adjacent ligand-free
monomer using PyMOL.Biotin-4-fluorescein off-rate assay
The off-rate of biotin-4-fluorescein (Life Technologies) was
measured from the fluorescence increase of biotin-4-
fluorescein upon unbinding from streptavidin at 37 °C with
competing free biotin (Sigma-Aldrich), as previously de-
scribed [36]. Samples (180 μL) in a sealed clear 96-well
microtiter plate containing 1 μM streptavidin variant in PBS
were incubated with 12 nM biotin-4-fluorescein at 37 °C for
1 h. We then added 1 mM biotin (20 μL) and biotin-4-
fluorescein release was monitored from the increase in
fluorescence (λex = 480 nm, λem = 520 nm) using a
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The percentage of dissociationwas calculated as (signal with
biotin − signal without biotin)/(signal without quenching −
signal without biotin) × 100. The signal without quenching
was taken as the biotin-4-fluorescein fluorescence in the
absenceof streptavidin. One-wayANOVAstatistical analysis
with Tukey'smultiple comparison test for the dissociation rate
curves was performed using the Prism program (GraphPad
Software).Biotin-4-fluorescein titration
To 20 nM streptavidin variant in PBS was added 0 to
15 nM biotin-4-fluorescein. Samples were incubated for
1 h at 37 °C in PBS. Subsequently, the fluorescence was
measured (λex = 485 nm, λem = 523 nm) using a
SpectraMax M5 plate reader (Molecular Devices).Biotinylated DNA gel shift
A monobiotinylated 439-bp PCR product was prepared
using Taq polymerase with primer Fts1 and terminally
biotinylated primer bioFts3 (5′ biotin triethylene glycol
linker), as previously described [36]. Streptavidin variant
(100 nM) was incubated with 50 nM monobiotinylated
PCR product in electrophoretic mobility shift assay buffer
(20 mM Hepes, pH 7.9, 1 mM reduced dithiothreitol,
0.1 mM ethylenediaminetetraacetic acid, 50 mM KCl, 5%
glycerol, and 0.2 mg/mL bovine serum albumin) for the
indicated time at 37 °C, mixed with 2× loading buffer [10%
glycerol, 2 mg/mL Orange G (Sigma-Aldrich)], and run on a
1.5% agarose gel containing ethidium bromide with TAE
(40 mM Tris–HCl, 20 mM acetic acid, and 1 mM ethyle-
nediaminetetraacetic acid, pH 8.3) for 1 h at 130 V. Gels
were imaged under UV using a ChemiDoc XRS imager
and QuantityOne (version 4.6) software.
For Fig. 7b, the indicated concentration of the strepta-
vidin variant was incubated with 50 nM of the monobioti-
nylated PCR product in electrophoretic mobility shift assay
buffer for 16 h at 25 °C, before mixing with loading buffer
and agarose electrophoresis as above.Dye labeling
SAe1D3 was labeled with AlexaFluor 555 succinimidyl
ester (Life Technologies) according to the manufacturer's
instructions. After conjugation (10:1 dye:streptavidin mono-
mer), excess dye was first removed by gel filtration on a
PD10 column (GEHealthcare) and subsequently by dialysis
three times against excess PBS. The number of dye
molecules per streptavidin monomer was calculated,
following manufacturer's instructions, from A280 and A555
to be 1.2.Cell culture and receptor labeling
HeLa cells (American Type Culture Collection) were
grown in high-glucose Dulbecco's modified Eagle's
medium with 10% fetal bovine serum (GE Healthcare),
50 U/mL penicillin, and 50 μg/mL streptomycin (growth
medium). HeLa cells were either co-transfected withAP-GFP-LDLR and BirA-ER plasmids or transfected
with AP-GFP-LDLR plasmid alone using Lipofectamine
2000 and incubated overnight in growth medium supple-
mented with 10 μM biotin. Cells were then placed on ice,
rinsed with cold PBS-Mg (PBS + 5 mM MgCl2), and
labeled with 200 nM SAe1D3-AlexaFluor 555 in PBS-Mg
with 1% dialyzed bovine serum albumin for 15 min on ice.
After three washes with cold PBS-Mg, cells were imaged
live.
Microscopy
Cells were imaged using a wide-field DeltaVision fluores-
cence microscope (Applied Precision) with a 40× oil
immersion objective and Optovar lens (1.6×), using soft-
WoRx 5.0.0 software (Applied Precision). AlexaFluor 555
was imaged with 540DF40 excitation, 600DF50 emission,
and a Chroma 84100bs polychroic filter set. Typical
exposure times were 0.1–0.5 s. Samples shown in the
same figure were imaged, analyzed, and displayed under
identical conditions.
Accession numbers
Coordinates and structure factors have been deposited
with PDB ID: 4BX5 for cis-divalent streptavidin, PDB ID:
4BX6 for 1,3 trans-divalent ligand-free streptavidin, and
PDB ID: 4BX7 for 1,3 trans-divalent streptavidin bound to
biotin-4-fluorescein.
Supplementary data to this article can be found online at
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